Search

740 Result(s)
Sort by

Disentangling fibrosis

Disentangling fibrosis

Fibrosis is an important area of research for Boehringer Ingelheim that is focusing on fibrotic conditions of the liver, lung, kidney, skin and gut.
CHMP_opinion_nintedanib_ILD_PF

CHMP_opinion_nintedanib_ILD_PF

Nintedanib received a CHMP positive opinion for the treatment of patients with other chronic fibrosing ILDs with a progressive phenotype beyond IPF
emperor-reduced-heart-failure-toplineresults

emperor-reduced-heart-failure-toplineresults

Positive, top-line results announced from the EMPEROR-Reduced Phase III trial in adults with chronic heart failure with reduced ejection fraction
EMPERIAL-heart-failure-toplineresults

EMPERIAL-heart-failure-toplineresults

Update on the EMPERIAL-Reduced and EMPERIAL-Preserved studies, which assess exercise ability in adults with chronic heart failure with reduced and preserved ejection fraction
A guide to hidradenitis suppurativa (HS)

A guide to hidradenitis suppurativa (HS)

Hidradenitis suppurativa (HS) is a long-term, inflammatory, recurrent, skin condition that causes painful inflamed nodules, or abscesses on the skin
Supporting Fundappas

Supporting Fundappas

Supporting Fundappas in Uruguay to improve quality of life of dogs and people.
Phase II trials for patients with bronchiectasis

Phase II trials for patients with bronchiectasis

Bronchiectasis is a chronically progressive pulmonary disease. Boehringer Ingelheim investigates a potential new treatment option in two Phase II trials.
Protein Degraders in Cancer

Protein Degraders in Cancer

Boehringer Ingelheim scientists and their partners are exploring how protein degraders could bring so-called undruggable cancer targets within reach
emperor-preserved-chmp-positive-opinion

emperor-preserved-chmp-positive-opinion

CHMP issues positive opinion to expand Jardiance (empagliflozin) indication based on unprecedented benefit in adult heart failure patients with preserved ejection fraction
real-world-benefit-shown-in-T2D-treatment

real-world-benefit-shown-in-T2D-treatment

Real-world evidence study shows type 2 diabetes treatment reduced risk of cardiovascular events and hospitalization for heart failure
Rethinking mental health care

Rethinking mental health care

Outdated perceptions and practices fuelling mental health crisis, new Economist Impact study reveals
emperor-preserved-heart-failure-full-data

emperor-preserved-heart-failure-full-data

Full results from EMPEROR-Preserved trial demonstrate significant improvement in heart failure outcomes in adults with preserved ejection fraction
empa-reg-outcome-recurrent-events

empa-reg-outcome-recurrent-events

EMPA-REG OUTCOME® analysis: Empagliflozin reduced risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and CV disease
H5N1: Bird flu again. What’s different now?

H5N1: Bird flu again. What’s different now?

H5N1: how is avian influenza now? The virus known for affecting wild & domestic birds has been detected in dairy cows in the US. What you need to know.